Damora Therapeutics (DMRA) Net Income by Year
Damora Therapeutics, Inc. reported a net loss of $209.8M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a $291.7M net loss. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Damora Therapeutics, Inc. has filed alongside them.
Ticker history: GLTO became DMRA (Damora Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View GLTO history.
Annual figures, oldest first. Point at a bar to read its period.
DMRA Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
DMRA Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Damora Therapeutics, Inc. financials
Frequently Asked Questions
Damora Therapeutics, Inc. reported a net loss of $209.8M in fiscal year 2025.
Damora Therapeutics, Inc. (DMRA) reported a $21.4M net loss in fiscal year 2024 and a $209.8M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Damora Therapeutics, Inc. (DMRA) reported a $291.7M net loss over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Across the 7 fiscal years this page covers, Damora Therapeutics, Inc. (DMRA) net income went from -$36.5M in fiscal year 2019 to -$209.8M in fiscal year 2025.
Damora Therapeutics, Inc. (DMRA) reported -$32.0M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Damora Therapeutics, Inc. (DMRA) reported on that line in every period on record.